French health authorities suspend use of Valneva SE's single-dose chikungunya vaccine in elderly individuals due to adverse effects
From GlobeNewswire: 2025-04-26 13:10:00
Valneva SE, a vaccine company, faces a setback as French health authorities suspend the use of its single-dose chikungunya vaccine, IXCHIQ®, in people aged 65 and older due to reports of severe adverse effects, including hospitalizations and one death among elderly individuals with preexisting conditions in La Réunion. Despite the ongoing vaccination campaign in response to a chikungunya outbreak on the island, Valneva is cooperating with regulatory authorities to address the situation. The company has supplied 40,000 doses of IXCHIQ® to La Réunion so far.
Chikungunya is a viral disease spread by infected Aedes mosquitoes, causing fever, joint pain, headaches, and fatigue. The outbreak of chikungunya in La Réunion has prompted French health authorities to revise vaccination priorities and safety measures. Valneva is actively collaborating with regulatory agencies to ensure the safety and efficacy of its vaccines amidst the evolving situation. The economic and medical impact of chikungunya remains a significant public health concern, with the disease spreading to over 110 countries globally. Valneva remains committed to developing prophylactic vaccines for infectious diseases with unmet medical needs.
Read more at GlobeNewswire: Valneva fait un point sur la recommandation d’utilisation